Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Yong Mun
Treatment patterns and outcomes for second-line therapy in large B-cell lymphoma: results from the LEO CReWE study
Abstract Treatment strategies for relapsed/refractory large B-cell lymphoma (R/R LBCL) have evolved rapidly, yet relationships between therapy selection and outcomes remain poorly defined. The LEO CReWE study evaluated disease characteristics, patterns of care, and outcomes in 1504 patients with R/R LBCL from 2002 to 2022. Of these, 64% received chemoimmunotherapy at second-line (2L).
Beyond Liu Bei and Cao Cao: The real lessons of the Three Kingdoms
LETTER | I read with interest Selangor Menteri Besar Amirudin Shari’s use of “Romance of the Three Kingdoms” to contrast Liu Bei with Cao Cao as an analogy for the type of leadership Malaysians should embrace. While the comparison is politically appealing, it simplifies one of the most enduring works on political philosophy and statecraft in Chinese literature.
Experimental and Clinical Studies on the Therapeutic Effects of Koryo Medicine-Rapid Coronary Blood Flow Enhancer Atherosclerosis and Some Ischemic Heart Diseases | International Journal of Clinical and Experimental Physiology
Chol Yong Ri Department of Biochemistry, Medical Faculty No 1, Haeju College of Medical Sciences, Haeju, DPRK, DEMOCRATIC PEOPLE’S REPUBLIC of KOREA. Yong Il Mun Department of Biochemistry, Medical Faculty No 1, Haeju College of Medical Sciences, Haeju, DPRK, DEMOCRATIC PEOPLE’S REPUBLIC of KOREA. Mae Ri Department of Biochemistry, Medical Faculty No 1, Haeju College of Medical Sciences, Haeju, DPRK, DEMOCRATIC PEOPLE’S REPUBLIC of KOREA.
Association of race/ethnicity and insurance with survival in patients with diffuse large B‐cell lymphoma in a large real‐world cohort
1 INTRODUCTION Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL), accounting for approximately 30% of all NHL diagnoses.1 DLBCL is a highly heterogenous, aggressive hematological malignancy typically presenting with rapidly enlarging lymphadenopathy and constitutional symptoms, requiring urgent treatment.2 More than 18,000 patients are diagnosed with DLBCL each year in the United States (predominantly males), with a 5-year relative survival rate of...
Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials | Melanoma | JAMA Oncology | JAMA Network
Key Points Question What are the clinical and genomic factors associated with survival outcomes in patients with BRAF V600–mutated metastatic melanoma treated with BRAF and/or MEK inhibitors?
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Yong
Contact Yong, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack